Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice by Hinkle, Richard T et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Medicine
Open Access Research article
Corticortophin releasing factor 2 receptor agonist treatment 
significantly slows disease progression in mdx mice
Richard T Hinkle1, Frank R Lefever1, Elizabeth T Dolan1, 
Deborah L Reichart1, Jefferey A Dietrich1, Kathryn E Gropp1, 
Robert I Thacker2, Jeffrey P Demuth1, Paula J Stevens1, Xiaoyan A Qu1, 
Alex R Varbanov1, Feng Wang1 and Robert J Isfort*1
Address: 1Research Division, Procter & Gamble Pharmaceuticals, Mason, OH, USA and 2Department of Pathobiology and Molecular Medicine, 
University of Cincinnati, Cincinnati, OH, USA
Email: Richard T Hinkle - hinkle.rt.2@pg.com; Frank R Lefever - lefever.fr@pg.com; Elizabeth T Dolan - dolan.et@pg.com; 
Deborah L Reichart - reichart.dl@pg.com; Jefferey A Dietrich - dietrich.ja@pg.com; Kathryn E Gropp - gropp.ke@pg.com; 
Robert I Thacker - thackeri@email.uc.edu; Jeffrey P Demuth - demuth.jp@pg.com; Paula J Stevens - stevens.pj@pg.com; 
Xiaoyan A Qu - qu.ax@pg.com; Alex R Varbanov - varbanov.ar@pg.com; Feng Wang - wang.f@pg.com; Robert J Isfort* - isfort.rj@pg.com
* Corresponding author    
Abstract
Background:  Duchenne muscular dystrophy results from mutation of the dystrophin gene,
causing skeletal and cardiac muscle loss of function. The mdx mouse model of Duchenne muscular
dystrophy is widely utilized to evaluate the potential of therapeutic regimens to modulate the loss
of skeletal muscle function associated with dystrophin mutation. Importantly, progressive loss of
diaphragm function is the most consistent striated muscle effect observed in the mdx mouse model,
which is the same as in patients suffering from Duchenne muscular dystrophy.
Methods: Using the mdx mouse model, we have evaluated the effect that corticotrophin releasing
factor 2 receptor (CRF2R) agonist treatment has on diaphragm function, morphology and gene
expression.
Results: We have observed that treatment with the potent CRF2R-selective agonist PG-873637
prevents the progressive loss of diaphragm specific force observed during aging of mdx mice. In
addition, the combination of PG-873637 with glucocorticoids not only prevents the loss of
diaphragm specific force over time, but also results in recovery of specific force. Pathological
analysis of CRF2R agonist-treated diaphragm muscle demonstrates that treatment reduces fibrosis,
immune cell infiltration, and muscle architectural disruption. Gene expression analysis of CRF2R-
treated diaphragm muscle showed multiple gene expression changes including globally decreased
immune cell-related gene expression, decreased extracellular matrix gene expression, increased
metabolism-related gene expression, and, surprisingly, modulation of circadian rhythm gene
expression.
Conclusion: Together, these data demonstrate that CRF2R activation can prevent the progressive
degeneration of diaphragm muscle associated with dystrophin gene mutation.
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Background
Duchenne muscular dystrophy (DMD) is a lethal progres-
sive muscle-wasting disease with an incidence of 1 in
3500 live male births [1-3]. Duchenne muscular dystro-
phy is usually diagnosed by age 4 or 5 and results in the
progressive loss of striated muscle function (including
diaphragm function), cardiac malfunction, loss of mobil-
ity and muscle strength, such that DMD patients are typi-
cally wheelchair-bound by age 12, with death from
respiratory and heart failure usually occuring by the late
teens or early twenties [1-3]. DMD and the less severe, yet
related, Becker muscular dystrophy (BMD) both result
from mutation of the dystrophin gene [1-3]. The dys-
trophin gene is an X chromosome-linked gene that is one
of the largest known, coding for a 427 kDa protein [1-3].
Dystrophin is a member of a multicomponent complex
with multiple functions, including connecting the
cytoskeleton to the extracellular matrix, reinforcing the
sarcolemma to prevent membrane tearing during myocyte
contraction, modulating calcium influx in the myocyte,
and serving as a nucleation site for many enzymatic activ-
ities including nitric oxide synthetase [1-3].
The current treatment for DMD is corticosteroid therapy
[2,4-7]. It has been observed that high-dose corticosteroid
treatment, specifically with prednisone and deflazacort,
slows disease progression through an as yet unknown
mechanism [2,4-7]. Other treatment modalities currently
being evaluated include gene replacement therapy, stem
cell transfer, protease inhibitors, exon skipping therapeu-
tics and translation modulating agents, such as aminogly-
cosides [2,4,5,7].
There are several animal models of DMD, including the
mouse mdx model [8,9]. The mdx mouse resulted from a
spontaneous mutation of the dystrophin gene that caused
the formation of a premature stop codon and truncation
of the dystrophin protein [8,9]. Mdx mouse striated mus-
cle is normal at birth but undergoes a spontaneous degen-
eration/regeneration event at approximately 3 weeks of
age [8,9]. After the regeneration event, mdx mouse stri-
ated muscle undergoes continual deterioration until pre-
mature death occurs [8,9]. Interestingly, in the mdx
mouse the diaphragm undergoes rapid and continual
deterioration while the limb muscles and the heart are less
affected; this is in contrast to DMD patients where limb
muscle and cardiac deterioration occurs at a similar rate to
diaphragm degeneration [8-12]. Thus, the diaphragm is
often used for evaluating the therapeutic potential of com-
pounds in the mdx mouse model of DMD [8-12]. The
mdx mouse model has been used to evaluate a number of
compounds for efficacy, and correlation between the mdx
mouse model and DMD patients appears to be quite good
[2,9].
Recently, we have shown that corticotrophin releasing fac-
tor receptor 2 (CRF2R) agonists can modulate skeletal
muscle mass by increasing muscle mass (hypertrophy)
and decreasing loss from atrophying/wasting of muscle
mass [13-15]. These effects occur by decreasing proteoly-
sis during atrophying conditions and activation of ana-
bolic signalling pathways [13-15]. Therefore, we have
utilized potent CRF2R agonists in the mdx model in order
to evaluate the therapeutic potential for these compounds
in DMD.
Methods
Materials
The CRF2R selective agonist PG-873637 was synthesized
at Procter & Gamble Pharmaceuticals (Cincinnati, OH,
USA) as described previously [16-18]. Prednisone, Tween
80, and benzyl alcohol were purchased from SIGMA (St
Louis, MO, USA). Methyl cellulose was purchased from
Aldrich. Male 2 and 3 month old C57BL/10-DMDmdx and
C57BL/10 mice were purchased from the Jackson Labora-
tories (Bar Harbor, ME, USA). Mice were single-housed
and acclimatized to the conditions of the facility for
approximately 1 week before use. Mice had access to lab
chow and water ad libitum and were subjected to standard
conditions of humidity, temperature and a 12-hour light
cycle. All studies described in this report were conducted
in compliance with the US Animal Welfare Act, the rules
and regulations of the State of Ohio Departments of
Health, and in accordance with the Procter & Gamble
Company policy on research involving animals with strict
oversight for care and welfare. For details of the policy
please contact the Procter & Gamble Company.
Dosing and diaphragm functional analysis
PG-873637 was administered at 30 ug/kg by daily subcu-
taneous injection. Prednisone was administered at 1 mg/
kg by daily subcutaneous injection. The vehicle for PG-
873637 was 0.9% sodium chloride/0.2% Tween 80/
water, while the vehicle for prednisone was 0.9% sodium
chloride/1% methyl cellulose/1% benzyl alcohol/0.2%
Tween 80/water. At the end of the study, mice were anes-
thetized with isoflurane, the mid-section of the mouse
shaved, a lateral incision was made just below the ribcage,
and the spinal cord cut to exsanguinate the animal. The
diaphragm was then removed still attached to the ribs,
placed in a Petri dish containing 25°C oxygenated (95%
oxygen/5% carbon dioxide) Krebs-Ringer solution (137
mM sodium chloride, 24 mM sodium bicarbonate, 11
mM glucose, 5 mM potassium chloride, 1 mM magne-
sium sulfate, 1 mM sodium phosphate, pH 7.4). The dia-
phragm was cut into hemispheres, and the larger
hemisphere containing the vertebrate was discarded. The
smaller hemisphere was spread, pinned, a needle contain-
ing suture material was inserted through one of the ribs
and tied, a section of diaphragm was cut from the rib toBMC Medicine 2007, 5:18 http://www.biomedcentral.com/1741-7015/5/18
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the central tendon parallel to the muscle fibers, and the
central tendon was tied to suture. The diaphragm strip was
then placed in a 25°C oxygenated bath containing Krebs-
Ringer solution containing 0.025 mM d-turbocurarine
chloride with one end attached to a force transducer and
the other end attached to a fixed post for contractile prop-
erties testing. Diaphragm strips were aligned horizontally
between a servomotor lever arm and the stainless steel
hook of a force transducer (Aurora Scientific Inc., model
6650 LR) and field-stimulated by pulses transmitted
between two platinum electrodes placed longitudinally
on either side of the muscle. Square wave pulses (0.2 ms
duration) generated by a personal computer with a Lab-
view board (Model PCI-MIO-16E-4, Labview Inc., Austin,
TX, USA) were amplified (Acurus Power Amplifier Model
A250, Dobbs Ferry, NY, USA) to increase and sustain cur-
rent intensity to a sufficient level to produce a maximum
isometric titanic contraction. Testing included maximiz-
ing stimulation voltage and optimizing muscle length for
maximum force development during twitch (1 Hz). Fol-
lowing twitch measurements, the diaphragm strip was
stimulated at increasing frequencies (10–300 Hz) until a
maximum tetanic force (Po) was obtained. At the end of
the measurement of force, the diaphragm strip was meas-
ured from myotendinous junction to the point of inser-
tion on the rib and optimal length (Lo) was obtained.
Stimulation voltage and muscle length (Lo) were adjusted
to obtain maximum isometric twitch force. Maximum
tetanic force production (Po) was determined from the
plateau of the frequency-force relationship. Immediately
after testing, the muscle was trimmed of tendon and extra-
neous tissue and weighed. Additional strips of diaphragm
muscle were removed, with one strip at resting length
placed in formalin for histomorphological and myofiber
cross-sectional area analysis, and a second strip snap fro-
zen in liquid nitrogen for expression profiling analysis.
Myofiber cross-sectional area analysis
Myofiber cross-sectional area analysis was performed on
10% neutral buffered formalin fixed resting length dia-
phragm muscle preparations from every treated animal.
Following paraffin embedding, cross-sections were cut
from the diaphragm muscle strip in triplicate. Sections
were stained with Picro-sirius Red (Sirius red F3B, C.I.
35782), which stains endomysium collagen red resulting
in clearly delineated and easily digitalized muscle fibers
(myofibers stain light yellow). Digital images of the
stained samples were acquired using a SPOT RT camera
and the SPOT Advanced Imaging Software (Universal
Imaging Corp., Downingtown, PA, USA) from the center
third of each section. Automated segmentation and
myofiber cross-sectional area measurements, based on
differential staining of the endomysium and myofibers,
was performed using custom software developed at
Procter & Gamble Pharmaceuticals. Aphelion 3.2 software
(Amerinex Applied Imaging, Amherst, MA, USA) was used
to manually edit the processed images in order to ensure
accurate measurement of only myofiber cross-sectional
area. An average of approximately 165 myofibers per dia-
phragm per animal were evaluated.
Histopathological analysis
Formalin-fixed diaphragm tissue was paraffin embedded,
cross-sectioned and stained with either hematoxylin and
eosin (H&E) or Masson's trichrome stain. The stained sec-
tions were evaluated and scored blind to treatment group
by a Board Certified Pathologist (KEG) for inflammation
and muscle fiber pathology (H&E stain) and fibrosis
(Masson's trichrome stain). The severity of inflammation
and fibrosis was graded on a six-point scale (none = 0,
minimal = 1, slight = 2, mild = 3, moderate = 4, marked =
5) for each sample, with a composite score recorded and
average severity score determined.
Statistical analysis of animal data
Statistical analysis of the data was performed using an
ANCOVA model with treatment effect and starting weight
as the covariates. Pairwise comparisons for all end-points
were generated using least-square means (SAS, Cary, NC,
USA), adjusted for unequal sample sizes and starting
weight.
Expression profiling analysis
Snap frozen diaphragm muscle strips were homogenized
in Trizol (Life Technologies, Rockville, MD, USA) using
tungsten carbide beads (Qiagen, Chatsworth, CA, USA)
with shaking in a mixer mill (Qiagen) as recommended
by the manufacturer. RNA samples were prepared accord-
ing to the recommendations of the manufacturer
(Affymetrix; Santa Clara, CA, USA). Briefly, total RNA was
prepared with the use of Trizol reagent (Life Technolo-
gies). After the Trizol extraction, the RNA was purified
with a RNeasy Mini Kit (Qiagen). Reverse transcription
was performed on 10 ug of total RNA with the use of
SuperScript II reverse transcriptase and a T7-(dT)24 primer
followed by second strand DNA synthesis utilizing T4
DNA polymerase (all from Life Technologies) as recom-
mended by the manufacturer. Contaminants were
removed from the double-stranded cDNA by phenol-
chloroform-isoamyl alcohol extraction and then cDNA
was recovered by ethanol precipitation. A RNA Transcript
Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA)
was used for production of biotin-labeled cRNA (comple-
mentary RNA) targets by in vitro transcription from T7
RNA polymerase promoters, all as recommended by the
kit manufacturer. The cDNA prepared from total RNA was
used as a template in the presence of a mixture of unla-
beled ATP, GTP, CTP and UTP and biotinylated CTP and
UTP. In vitro transcription products were purified with an
RNeasy Mini Kit (Quiagen) to remove unincorporatedBMC Medicine 2007, 5:18 http://www.biomedcentral.com/1741-7015/5/18
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NTPs and fragmented to approximately 35 to 200 bases by
incubation at 94°C for 35 min in fragmentation buffer
containing tris-acetate, potassium acetate, and magne-
sium acetate. Fragmented cRNA was stored at -20°C until
the hybridization was performed. Biotinylated and frag-
mented cRNA was hybridized for 16 h at 45°C to mouse
MOE430Plus arrays (Affymetrix) in a GeneChip Hybridi-
zation Oven 640 (Affymetrix). A series of stringency
washes and staining with streptavidin-conjugated phyco-
erythrin was then performed in a GeneChip Fluidic Sta-
tion 400 (Affymetric) according to the protocol
recommended by Affymetrix. Probe arrays were then
scanned with an Agilent GeneArray Scanner. The images
were analyzed with the GeneChip Analysis software
(Affymetrix).
Statistical analysis of expression profiling data
The initial statistical analysis was focused on determining
"outlier" chips. This includes exploratory data analysis
using chip-descriptive statistics, pair plots, and principal
component analysis. After "outlier" chips are eliminated
from further statistical analysis, the gene expression signal
(based on Affymetrix MAS 5.0 algorithm) is preprocessed
using scaling and quantile normalization, and trans-
formed to log (base 2) scale. Following this, an analysis of
variance (ANOVA) statistical model was utilized to esti-
mate Log fold change (LFC) and corresponding uncer-
tainty measure, standard error (SE), for the paired
conditions of interest. The ratio of LFC to SE was investi-
gated to determine the statistical significance of the differ-
ential gene expression between two compared
experimental conditions. Statistical significance was sum-
marized by a quantity called NLOGP (= -log10 [P-value]).
An NLOGP threshold equal to -log10(average false posi-
tive rate) is used to detect genes with statistically signifi-
cant differential expression (corresponding NLOGP
measure is greater than the NLOGP threshold). All data
was tabulated as fold change in expression relative to the
0 timepoint. A gene is considered to be differentially
expressed if all of the following three rules hold:
1. The NLOGP measure is greater than the threshold
(NLOGP = 4.0).
2. There are at least 50% Affymetrix present calls for the
overexpressed condition in the comparison.
3. The fold change is at least 1.2.
Results of bioinformatics analysis of expression profiling
To assign annotation to the differentially-expressed genes
to gain the best understanding of the functional roles they
play in their respective biological processes, a variety of
public resources as well as proprietary tools were used.
These included: Affymetrix Netaffx analysis database
(Affymetrix: Santa Clara, CA, USA), GeneCard (Weiz-
mann Institute of Science, Israel), UniGene, RefSeq and
LocusLink (NCBI, Bethesda, MD, USA), SwissProt/
TrEMBL (Swiss Institute of Bioinformatics, Switzerland),
FANTOM2 (RIKEN Yokohama Institute, Japan), and The
Institute of Genomics Research (TIGR) Gene Index (Bos-
ton, MA, USA) databases. For those uncharacterized genes
or ESTs, a semi-automatic annotation strategy was used
that combined the following steps: (1) Homology search-
ing against the major nucleotide and protein databases,
including NCBI-nr (Bethesda, MD, USA), Ensembl (Euro-
pean Bioinformatics Institute, Germany) and SwissProt/
SPTreMBL (Swiss Institute of Bioinformatics, Switzerland)
using BLASTX/BLASTP (NCBI, Bethesda, MD, USA); (2)
derivation of function from homolog/orthlog databases,
including HomoloGene (NCBI, Bethesda, MD, USA) and
TIGR Resourcerer/TOGA (Boston, MA, USA) databases;
(3) assignment or prediction of functional roles by pro-
tein motif search using PFAM (Protein Family Database)
(Welcome Trust Sanger Institute, Cambridge, UK), Prosite
(Swiss Institute of Bioinformatics, Switzerland), and/or
InterPro (European Bioinformatics Institute, Germany).
In addition, curation from bioinformatics efforts was
applied, based upon the available biomedical literature
sources.
Results
Experimental design and goals
For all experiments, mdx mice at 2–3 months of age (at
study start) were utilized. We chose this age for the mice
because the major myofiber death/regeneration event is
over, and the mice showed a steady progressive loss of dia-
phragm specific force with time (in mdx mice at 2–3
months of age there is about 50% loss ofdiaphragm spe-
cific force compared to C57BL10 wild-type mice – Figure
3). We investigated diaphragm muscle as it has been
shown previously that mdx diaphragm muscle, unlike
limb muscles, undergoes a progressive loss of function
similar to that observed in DMD patients. The goal of the
first experiment was to evaluate the effect of daily subcu-
taneous injection treatment with 1 mg/kg of prednisone,
a glucocorticoid that has been shown to have efficacy at
this dose in the mdx model and DMD patients [6,19,20],
and a CRF2R agonist (PG-873637), either alone or in
combination. In the first experiment, we assessed the fol-
lowing variables: 3-month-old mdx mice untreated (dia-
phragm muscle was analyzed at the start of the study;
control time 0), mdx mice treated for 3 months with vehi-
cle by once-daily subcutaneous injection (vehicle), mdx
mice treated for 3 months with 1 mg/kg of prednisone by
once-daily subcutaneous injection (prednisone), mdx
mice treated for 3 months with 30 ug/kg PG-873637 by
once-daily subcutaneous injection (PG-873637), and
mdx mice treated for 3 months with 1 mg/kg prednisone
and 30 ug/kg PG-873637 by once-daily subcutaneousBMC Medicine 2007, 5:18 http://www.biomedcentral.com/1741-7015/5/18
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injection (prednisone + PG-873637). At the end of the
study, diaphragm function, histomorphology and
myofiber cross-sectional area were analyzed. The goal of
the second experiment was to evaluate the effect of daily
subcutaneous injection treatment with a CRF2R agonist
(PG-873637) on diaphragm function and gene expres-
sion. In the second experiment, we assessed the following:
2-month-old mdx mice untreated with diaphragm analy-
sis at 2 months of age (mdx control time 0), mdx mice
treated for 3 months with vehicle by once-daily subcuta-
neous injection (mdx vehicle), mdx mice treated for 3
months with 30 ug/kg PG-873637 administered by once-
daily subcutaneous injection (mdx PG-873637), 2-
month-old C57BL10 mice untreated with diaphragm
analysis at 2 months of age (C57BL10 control time 0),
and C57BL10 mice treated for 3 months with vehicle by
once-daily subcutaneous injection (C57BL10 vehicle). At
the end of the study, diaphragm function and gene expres-
sion were analyzed.
Effect of CRF2R agonist and corticosteroid treatment on 
mdx diaphragm muscle function and structure
In experiment 1 we observed the following: 3 months of
daily subcutaneous vehicle injection of mdx mice resulted
in an approximate 20% loss of diaphragm specific force;
treatment with 1 mg/kg of prednisone abrogated most of
the loss of diaphragm specific force (p = 0.09 versus vehi-
cle); treatment with 30 ug/kg of PG-873637 completely
blocked the loss of diaphragm specific force (p < 0.05 ver-
sus vehicle); and treatment with 1 mg/kg prednisone plus
30 ug/kg PG-873637 not only abrogated the loss of dia-
phragm specific force (p < 0.05 versus vehicle) but
increased diaphragm specific force over that observed at
time 0 (p = 0.09 versus time 0) (Figure 1 and Table 1).
Diaphragm muscle myofiber cross-sectional area changes
were in parallel with the time- and treatment-related
changes observed in diaphragm specific force; diaphragm
muscle mass was increased at all time and treatment data
points relative to time 0, diaphragm absolute force
increased with PG-873637 and PG-873637 + prednisone
treatment, and there were relatively few time- and treat-
ment-related changes in diaphragm muscle peak twitch
force, half relaxation time, and time to peak tension
(Table 1). Histopathological analysis of the diaphragm
muscle from the various treatment groups of experiment
1 showed increased fibrosis following 3 months of vehicle
treatment relative to time 0; relative to vehicle treatment,
there was less fibrosis with prednisone, PG-873637, and
prednisone+PG-873637 treatment, and the fibrotic index
actually fell below time 0 with the combination treatment
of prednisone + PG-873637 treatment (Figure 2 and Table
2). There was no increase in inflammation in the dia-
phragm following 3 months of vehicle treatment; treat-
ment with prednisone, PG-873637, and prednisone + PG-
873637 decreased inflammation below the time 0 level
(Figure 2 and Table 2). The general histopathology for
diaphragms from mdx mice had typical findings for this
genotype: interstitial inflammation (lymphocytic and
mononuclear), interstitial fibrosis, internal myofiber
nuclei, increase in myofiber area variability, evidence of
myofiber regeneration, rare degenerative myofibers, rare
myofiber mineralization and infiltration of adipocytes.
Transcriptional profiling of CRF2R agonist-treated and 
untreated mdx diaphragm muscle and wild-type 
diaphragm muscle
In experiment 2, 3 months of daily subcutaneous vehicle
injection of mdx mice resulted in an approximate 20%
loss of diaphragm specific force ; treatment with 30 ug/kg
of PG-873637 blocked the loss of diaphragm specific
force (p < 0.05 versus vehicle; Table 3 and Figure 3). Com-
parison of the specific force of the time 0 diaphragm from
mdx mice to that of age-matched C57BL10 showed an
approximate 50% loss in specific force (Table 3 and Figure
3). Analysis of additional diaphragm muscle parameters
from experiment 2 did not demonstrate major differences
between the mdx-treated groups and the age-matched
Effect of 3 months of treatment on mdx diaphragm specific  force Figure 1
Effect of 3 months of treatment on mdx diaphragm 
specific force. Three-month-old mdx mice were treated by 
daily subcutaneous injection with the indicated compounds 
for 3 months and, at the end of treatment, the diaphragms 
were removed and evaluated for force production. Time 0, 3 
month old mdx mice before treatment. Vehicle, mdx mice 
treated for 3 months with vehicle. Prednisone, mdx mice 
treated for 3 months with 1 mg/kg of prednisone. PG-
873637, mdx mice treated for 3 months with 30 ug/kg of PG-
873637. PG-873637 + prednisone, mdx mice treated for 3 
months with the combination of 30 ug/kg PG-873637 plus 1 
mg/kg prednisone.
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C57BL10 controls (Table 3). Histopathological analysis of
the diaphragm muscle from experiment 2 showed similar
findings to those observed in experiment 1 (data not
shown). The diaphragm muscle from experiment 2 was
utilized for expression profiling analysis. For this analysis,
gene expression profiles were obtained from mdx time 0,
mdx 3 month vehicle-treated, mdx 3 month PG-873637-
treated, C57BL10 time 0 and C57BL10 3 month vehicle-
treated diaphragms. The number of statisticallysignificant
gene expression changes for the various comparisons are
as follows: mdx vehicle versus mdx time 0, 437 genes;
mdx PG-873637 versus mdx vehicle, 683 genes; C57BL10
vehicle versus mdx vehicle, 4636 genes. Multiple compar-
isons were made between these groups with the following
observations: the gene expression changes in common
between mdx PG-873637-treated versus mdx vehicle-
treated and mdx vehicle-treated and mdx time 0, 38 com-
mon genes; mdx PG-873637-treated versus C57BL10
vehicle-treated versus mdx vehicle-treated, 410 common
genes. For this report, only the comparison of statistically
significant changes in differential gene expression
between mdx PG-873637-treated and mdx vehicle-treated
is shown in Table 2 (also given in Table 2 are the differ-
ences in expression between mdx vehicle-treated versus
mdx time 0, C57BL10 vehicle-treated versus mdx vehicle-
treated, and C57BL10 vehicle-treated versus C57BL10
time 0 for comparison purposes). Comparisons between
mdx vehicle-treated versus mdx time 0 and C57BL10 vehi-
cle-treated versus mdx vehicle-treated are given in Addi-
Histomorphological analysis of diaphragm muscle from mdx  mice treated with vehicle, prednisone, PG-87367 and PG- 873637+prednisone for 3 months Figure 2
Histomorphological analysis of diaphragm muscle 
from mdx mice treated with vehicle, prednisone, PG-
87367 and PG-873637+prednisone for 3 months. 
Three-month-old mdx mice were treated by daily subcutane-
ous injection with the indicated compounds for 3 months and 
at the end of treatment, the diaphragms were removed and a 
histomorphological analysis performed. Time 0, 3 month old 
mdx mice before treatment. Vehicle, mdx mice treated for 3 
months with vehicle. Prednisone, mdx mice treated for 3 
months with 1 mg/kg of prednisone. PG-873637, mdx mice 
treated for 3 months with 30 ug/kg of PG-873637. PG-
873637 + prednisone, mdx mice treated for 3 months with 
the combination of 30 ug/kg PG-873637 plus 1 mg/kg pred-
nisone. The two photographs in each treatment group are 
from representative diaphragm sections from two different 
animals in each treatment group. All samples were hematox-
ylin and eosin stained.
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Effect of 3 months of treatment on either mdx or C57BL10  diaphragm specific force Figure 3
Effect of 3 months of treatment on either mdx or 
C57BL10 diaphragm specific force. Two-month-old 
mdx or C57BL10 mice were treated by daily subcutaneous 
injection with the indicated compound for 3 months and at 
the end of treatment, the diaphragms were removed and 
evaluated for force production. MDX Time 0, 2 month old 
mdx mice before treatment. MDX Vehicle, mdx mice treated 
for 3 months with vehicle. MDX PG-873637, mdx mice 
treated for 3 months with 30 ug/kg of PG-873637. C57BL10 
Time 0, 2 month old C57BL10 mice before treatment. 
C57BL10 Vehicle, C57BL10 mice treated for 3 months with 
vehicle.
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tional files 1, 2, 3, 4. As can be seen in Additional file 1,
differential gene expression between mdx PG-873637-
treated and mdx vehicle-treated diaphragm was observed,
with the genes demonstrating changes in expression in
many different functional classes including signal trans-
duction genes, proteolytic, extracellular matrix, protein
synthesis, metabolism, cytoskeleton/contractile appara-
tus, transport/channels and genes of unknown function.
Interestingly, most differential gene expression observed
between mdx PG-873637 treatment versus mdx vehicle
treatment were also observed between C57BL10 vehicle
treatment versus mdx vehicle treatments, indicating a nor-
malization of mdx muscle to a more wild-type phenotype.
In addition, most differential gene expression changes
between mdx PG-873637 treatment versus mdx vehicle
treatment in metabolism-related genes were increases in
expression, while those in the extracellular matrix-related
genes were decreases in expression. Subgroup analysis
(Additional file 2) showed that most changes in differen-
tial gene expression between mdx PG-873637 treatment
versus mdx vehicle treatment groups were also observed
in the C57BL10 vehicle treatment versus mdx vehicle
treatment groups, including immune cell expressed genes,
myofiber expressed genes and neuronal cell expressed
genes. Interestingly, dystrophin complex-related genes
showed differential expression for some but not all genes
when mdx PG-873637 treatment versus mdx vehicle treat-
ment was compared. In addition, an effect unique to PG-
873637 treatment was observed in the circadian rhythm
subgroup of genes; no changes in these genes were
observed in mdx vehicle-treated versus C57BL10 vehicle-
treated groups.
Discussion
In this report, we demonstrate that treatment of mdx mice
with a CRF2R agonist slows the loss of diaphragm specific
force that occurs during disease progression. The effect of
the CRF2R agonist is comparable to that observed with
glucocorticoid (prednisone) treatment. In addition, treat-
ment with the combination of a CRF2R agonist and glu-
cocorticoid not only slowed the loss of diaphragm specific
force associated with disease progression better than
either agent by itself, but this combination treatment actu-
ally increased diaphragm specific force to a level observed
before the start of the experiment. Histopathological anal-
ysis of CRF2R agonist-treated diaphragm showed a reduc-
tion in fibrosis, a reduction in inflammation, and
increased myofiber cross-sectional area. Finally, gene
expression changes showed that PG-873637 agonist treat-
ment decreased extracellular matrix gene expression and
reduced immune cell gene expression, findings that sup-
port the histopathological findings. Together, these obser-
Table 1: Summary of diaphragm muscle parameters from experiment 1. Effect of 3 months of treatment with either vehicle, 1 mg/kg 
prednisone, 30 ug/kg PG873637 or the combination of prednisone plus PG873637 on male 3-month-old (at time 0) mdx mice.
Time 0 Vehicle Prednisone PG-873637 PG-873637 + prednisone
Number of animals 10 10 10 9 8
Initial body mass (g) 28.49 (0.47) 28.53 (0.74) 28.36 (0.77) 28.39 (0.60) 27.37 (0.75)
Final body mass (g) 28.49 (0.47) 31.36† (0.90) 29.83† (0.62) 34.56† (0.38) 32.09† (0.48)
Diaphragm mass (g) 0.0031 (0.0002) 0.0035 (0.0003) 0.0038† (0.0002) 0.0041† (0.0003) 0.0038† (0.0003)
Diaphragm sPo (kN/m2) 96.478 (9.441) 74.100† (6.171) 90.340 (7.126) 95.811* (7.389) 116.91* (4.067)
Diaphragm Po (mN) 42.133 (3.239) 37.467 (4.043) 46.270 (2.720) 49.844* (3.557) 56.838*† (4.075)
Diaphragm Pt (mN) 11.511 (1.148) 9.778 (1.474) 12.470 (0.776) 10.278 (1.031) 12.063 (1.058)
Diaphragm HRT (ms) 56.289 (2.195) 50.222 (6.179) 51.070 (4.049) 50.089 (3.987) 45.875† (2.344)
Diaphragm TPT (ms) 33.511 (0.870) 33.989 (1.814) 33.650 (0.949) 31.267 (1.650) 29.588*† (0.685)
Diaphragm myofiber CSA 1634.2 (56.89) 1158.4† (55.55) 1429.5* (91.73) 1375.7*† (59.17) 1366.0*† (36.45)
sPo, muscle specific force; Po, muscle absolute force; Pt, muscle peak twitch force; HRT, muscle half relaxation time; TPT, muscle time to peak 
tension; CSA, myofiber cross-sectional area. All data are given as the mean with standard error of the mean in parenthesis. *Statistically significant 
difference (p < 0.05) versus the appropriate vehicle control; †statistically significant difference (p < 0.05) versus time 0.
Table 2: Summary of histopathology analysis for fibrosis and inflammation in H&E and Masson's trichrome stained diaphragm muscle 
from mdx mice in experiment 1. Effect of 3 months of treatment with either vehicle, 1 mg/kg prednisone, 30 ug/kg PG-873637 or the 
combination of prednisone plus PG-873637 on male 3-month-old (at time 0) mdx mice.
Time 0 Vehicle Prednisone PG-873637 PG-873637 + prednisone
Number of animals 10 10 10 9 8
Fibrosis 2.0 (0) 3.6† (0.16) 3.2† (0.25) 2.6*† (0.29) 1.9*‡ (0.13)
Inflammation 1.7 (0.26) 1.7 (0.15) 1.4 (0.16) 1.3* (0.15) 1.2* (0.15)
Diaphragm muscle samples were evaluated as described in Methods. All data are given as the mean with standard error of the mean in parenthesis. 
*Statistically significant difference (p < 0.05) versus the appropriate vehicle control; † statistically significant difference (p < 0.05) versus time 0; ‡ 
statistically significant difference (p < 0.05) versus PG-873637.BMC Medicine 2007, 5:18 http://www.biomedcentral.com/1741-7015/5/18
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vations indicate that treatment of mdx mice with a CRF2R
agonist slows the disease progression in mdx mice.
The mechanism by which CRF2R agonist treatment slows
disease progression in mdx mice is complex and involves
changes in most cell types that comprise diaphragm mus-
cle tissue. This includes: a direct effect on myofiber func-
tion, as evident from the increase in myofiber cross-
sectional area and changes in myofiber gene expression;
an effect on immune cell function that is evident from
reduced inflammation and reduced immune cell specific
gene expression in the treated mdx diaphragm; an effect
on fibroblasts and other connective tissue cells resulting
in reduced fibrosis and reduced extracellular matrix gene
expression; and effects on neuronal cells that are evident
from changes in neuronal cell specific gene expression.
Comparison of the relative levels of differential gene
expression in mdx diaphragm muscle following CRF2R
agonist treatment with that of age-matched C57BL10 dia-
phragm muscle demonstrates that CRF2R agonist treat-
ment reverts the mdx diaphragm to a more normal
phenotype. In summary, the histopathological and gene
expression changes resulting from CRF2R agonist treat-
ment leads to an apparent normalization of mdx dia-
phragm muscle.
How does CRF2R agonist treatment affect mdx diaphragm
function? In general, the data suggest that CRF2R agonist
treatment has multiple effects on the mdx diaphragm
muscle including increased myofiber cross-sectional area,
decreased fibrosis and decreased inflammation, all of
which probably contribute to the benefit observed. With
regard to specific mechanisms involved in the above-
described changes, several observations can be made from
the gene expression analysis. Firstly, changes in expression
of dystrophin complex-related genes; we did not observe
changes in the expression of dystrophin or utrophin,
nitric oxide synthase 1, dystroglycan 1 or dystrophin
related protein 2 [21]. We did, however, observe increased
expression of sarcoglycan alpha, sarcoglycan beta and dys-
trobrevin alpha. While these changes could result in
increased functionality of the dystrophin complex, with-
out the presence of dystrophin, it is difficult to understand
how these changes lead to improved functionality. More
work will be required in order to better understand
whether the CRF2R agonist induced changes in dys-
trophin-related complex genes translate into increased
protein and better functionality of the dystrophin com-
plex. Secondly, analysis of changes in immune cell spe-
cific genes demonstrates that the majority of these genes
show a decrease in expression following CRF2R agonist
treatment. This observation, along with histopathological
observation of decreased inflammation following CRF2R
agonist treatment, supports the concept that CRF2R ago-
nist treatment decreases immune cell activity in the dia-
phragm of mdx mice. Interestingly, three immune cell-
related genes showed a relative increase in expression fol-
lowing CRF2R agonist treatment: small chemokine (C-C
motif) ligand 11, interleukin 15 and nuclear factor of acti-
vated T-cells. Of these, interleukin-15 is particularly inter-
esting as it has been shown by Harcourt et al [22] that
interleukin 15 administration to mdx mice increases dia-
phragm function, increases diaphragm myofiber cross-
sectional area and decreases fibrosis. Thus, increased
expression of interleukin 15 following CRF2R agonist
treatment could contribute to the efficacy of the CRF2R
agonist treatment. Thirdly, in general extracellular matrix
gene expression decreased following CRF2R agonist treat-
ment. This observation, along with the histopathology
analysis, supports the observation of decreased fibrosis
associated with CRF2R agonist treatment. Two exceptions
to the general trend of decreased extracellular matrix gene
expression were noted – matrix metalloproteinase 24 and
tissue inhibitor of metalloproteinase 3, both of which
showed increased expression following CRF2R agonist
treatment. The significance of these two changes is at
Table 3: Summary of diaphragm muscle parameters from experiment 2. Effect of 3 months of treatment with either vehicle or 30 ug/
kg PG873637 on male 2-month-old (at time 0) mdx and C57BL10 mice.
Mdx time 0 Mdx Vehicle Mdx PG-873637 C57BL10 time 0 C57BL10 vehicle
Number of animals 10 9 11 10 10
Initial body mass (g) 21.90 (0.64) 22.43 (0.67) 22.32 (0.97) 24.21 (0.71) 24.69 (0.45)
Final body mass (g) 21.90 (0.64) 29.79† (0.50) 31.19† (0.63) 24.21 (0.71) 30.35† (0.66)
Diaphragm mass (g) 0.0027 (0.0002) 0.0040† (0.0003) 0.0043† (0.0002) 0.0023 (0.0001) 0.0027 (0.0002)
Diaphragm sPo (kN/m2) 120.12 (7.35) 91.90† (7.06) 112.58* (5.21) 210.22 (9.51) 196.49 (8.69)
Diaphragm Po (mN) 45.19 (5.92) 49.73 (5.46) 60.36† (3.09) 59.10 (3.75) 57.86 (3.98)
Diaphragm Pt (mN) 13.43 (1.72) 13.99 (1.40) 16.72 (1.05) 15.40 (1.04) 20.03* (1.51)
Diaphragm HRT (ms) 65.65 (2.75) 67.31 (4.42) 62.52 (2.49) 85.56 (3.44) 90.69 (6.27)
Diaphragm TPT (ms) 39.21 (1.31) 38.15 (1.26) 37.80 (0.56) 40.00 (0.86) 39.99 (1.14)
sPo, muscle specific force; Po, muscle absolute force; Pt, muscle peak twitch force; HRT, muscle half relaxation time; TPT, muscle time to peak 
tension. All data are given as the mean with standard error of the mean in parenthesis. *Statistically significant difference (p < 0.05) versus the 
appropriate vehicle control; † statistically significant difference (p < 0.05) versus time 0.BMC Medicine 2007, 5:18 http://www.biomedcentral.com/1741-7015/5/18
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present unknown, as two other matrix metalloproteinases
(14 and 3) showed decreased expression, as did tissue
inhibitor of metalloproteinase 1. These findings indicate
that extracellular matrix proteins are downregulated.
Fourthly, most metabolism-related genes showed
increases in expression to levels similar to those observed
in the C57BL10 muscle. Thus, CRF2R agonist treatment
normalized metabolic function of the muscle to a more
wild-type status, a change that probably contributes to
improvement in overall muscle functionality. Finally, the
most interesting group of gene expression changes associ-
ated with CRF2R activation were genes involved in the
control of circadian rhythm. We observed that treatment
of mdx mice with a CRF2R agonist increased the expres-
sion of the major circadian rhythm control genes includ-
ing period homolog 2 (PER2), period homolog 3 (PER3),
cryptochrome 2 (CRY2), thyrotroph embryonic factor
(TEF), nuclear receptor subfamily 1, group D member 2
(NR1D2), RAR-related orphan receptor alpha (RORA), D
site albumin promoter binding protein (DBP) genes and
decreased the expression of circadian locomoter output
cycles kaput (CLOCK) and aryl hydrocarbon receptor
nuclear translocator-like (ARNTL/BMAL1/MOP3) genes.
The CLOCK and ARNTL proteins function to activate
expression of a variety of clock genes via binding to an E-
box element, including PER, CRY, RORA and NR1D; PER
and CRY proteins then feedback to decrease the expres-
sion of ARNTL and CLOCK [23-25]. This regulatory con-
trol loop agrees well with the observation of CRF2R
agonist-mediated increased expression of PER 2, PER3,
CRY2, DBP, RORA and NR1D2 and decreased expression
of CLOCK and ARNTL. In addition to the changes in gene
expression of these major circadian rhythm control genes,
we also observed changes in the expression of other circa-
dian rhythm associated genes including the RevErbA/ROR
responsive element genes H3 histone, tubulin alpha,
splicing factor arginine/serine-rich, protein tyrosine phos-
phatase type IVa, LPS-induced TNF-alpha factor, solute
carrier family 25 and ADP-ribosylation factor; the DBP
responsive element genes fibroblast growth factor and
LPS-induced TNF-alpha factor; the E-box responsive ele-
ment genes tubulin alpha, growth arrest and DNA damage
inducible 45, adenylate kinase, solute carrier family,
mitogen-activated protein kinase kinase; the cAMP
responsive element genes dual specificity phosphatase,
RNA binding motif protein, B-cell translocation gene,
splicing factor arginine/serine-rich, protein tyrosine phos-
phatase type IVA, ADP-ribosylation-like factor 6 interact-
ing protein and ADP-ribosylation factor; and additional
genes such as glutathione S-transferase and UDP-glucose
pyrophosphorylase [24-26]. The function of CRF2R acti-
vation of circadian rhythm genes in muscle is as present
unknown. The known role of circadian rhythm in regulat-
ing metabolism [27-29] suggest that the changes in meta-
bolic gene expression observed following CRF2R
activation could be related to the change in circadian
rhythm gene expression. Also, it is possible that the same
changes that resulted in altered metabolic gene expression
could change circadian rhythm gene expression, as it has
been observed previously that changes in NAD and
NADPH modify circadian rhythm gene expression
[28,29]. Alternatively, CRF2R-mediated skeletal muscle
circadian rhythm modulation could be secondary to the
effects of CRF2R activation on food intake, as it is known
that modulation of food intake can change circadian
rhythm and CRF2R activation can decrease food intake
[28,30]. The changes in circadian rhythm resulting from
CRF2R activation could possibly be a result of cAMP mod-
ulation in skeletal muscle, as it has been shown previously
that CRF2R activation in skeletal muscle increases cAMP
levels [15] and modulation of intracellular cAMP (as well
as calcium and PKC) can affect circadian rhythm gene
expression [28]. Interestingly, other hormones associated
with the hypothalamus-pituitary-adrenal (HPA) axis can
potentially change circadian rhythm by acting as soluble
factors to synchronize the circadian rhythm in peripheral
tissues [28,31,32]. As the CRF2R is an integral part of the
HPA axis, the observation that activation of the CRF2R
modulates circadian rhythm gene expression in skeletal
muscle indicates a further function of the HPA axis in the
regulation of circadian rhythm. Obviously, more work
will be required to clearly understand the mechanism by
which activation of CRF2R can affect circadian rhythm
gene expression.
Conclusion
In summary, treatment of mdx mice with a CRF2R agonist
results in a slowing of disease progression. The magnitude
of this effect was equivalent to that observed with high-
dose glucocorticoid administration. In addition, the com-
bination of CRF2R agonist plus glucocorticoid not only
slowed disease progression but also actually reversed the
loss of specific force. Therefore, CRF2R agonists, such as
glucocorticoids, IL-15 and myostatin, have been shown to
have beneficial effects on diaphragm function in the mdx
model of DMD.
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